Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children.

Abstract

Convection-enhanced delivery (CED) for the treatment of malignant gliomas is a technique that can deliver chemotherapeutic agents directly into the tumor and the surrounding interstitium through sustained, low-grade positive-pressure infusion. This allows for high local concentrations of drug within the tumor while minimizing systemic levels that often lead to dose-limiting toxicity. Diffuse intrinsic pontine gliomas (DIPGs) are universally fatal childhood tumors for which there is currently no effective treatment. In this report the authors describe CED of the topoisomerase inhibitor topotecan for the treatment of DIPG in 2 children. As part of a pilot feasibility study, the authors treated 2 pediatric patients with DIPG. Stereotactic biopsy with frozen section confirmation of glial tumor was followed by placement of bilateral catheters for CED of topotecan during the same procedure. The first patient underwent CED 210 days after initial diagnosis, after radiation therapy and at the time of tumor recurrence, with a total dose of 0.403 mg in 6.04 ml over 100 hours. Her Karnofsky Performance Status (KPS) score was 60 before CED and 50 posttreatment. Serial MRI initially demonstrated a modest reduction in tumor size and edema, but the tumor progressed and the patient died 49 days after treatment. The second patient was treated 24 days after the initial diagnosis prior to radiation with a total dose of 0.284 mg in 5.30 ml over 100 hours. Her KPS score was 70 before CED and 50 posttreatment. Serial MRI similarly demonstrated an initial modest reduction in tumor size. The patient subsequently underwent fractionated radiation therapy, but the tumor progressed and she died 120 days after treatment. Topotecan delivered by prolonged CED into the brainstem in children with DIPG is technically feasible. In both patients, high infusion rates (> 0.12 ml/hr) and high infusion volumes (> 2.8 ml) resulted in new neurological deficits and reduction in the KPS score, but lower infusion rates (< 0.04 ml/hr) were well tolerated. While serial MRI showed moderate treatment effect, CED did not prolong survival in these 2 patients. More studies are needed to improve patient selection and determine the optimal flow rates for CED of chemotherapeutic agents into DIPG to maximize safety and efficacy. Clinical trial registration no.: NCT00324844.

• Authors: Richard C E Anderson, Benjamin Kennedy, Candix L Yanes, James Garvin, Michael Needle, Peter Canoll, Neil A Feldstein, Jeffrey N Bruce
• Journal: Journal of neurosurgery. Pediatrics (J Neurosurg Pediatr) Vol. 11 Issue 3 Pg. 289-95 (Mar 2013) ISSN: 1933-0715 [Electronic] United States
• PMID: 23240851 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Antineoplastic Agents
• Topotecan

Topics

• Antineoplastic Agents (administration & dosage, therapeutic use)
• Biopsy
• Brain (pathology)
• Brain Stem Neoplasms (diagnostic imaging, drug therapy)
• Child, Preschool
• Combined Modality Therapy
• Convection
• Drug Delivery Systems
• Fatal Outcome
• Female
• Gait Disorders, Neurologic (etiology)
• Glioma (diagnostic imaging, drug therapy)
• Humans
• Image Processing, Computer-Assisted
• Karnofsky Performance Status
• Magnetic Resonance Imaging
• Nervous System Diseases (etiology)
• Radiography
• Topotecan (administration & dosage, therapeutic use)
• Treatment Outcome